Finansinspektionen (the Swedish Financial Supervisory Authority) approved on May 13 Genovis prospectus for a new share issue with preference for existing shareholders, the subscription period is May 23 – June 8, 2016. Genovis AB (publ) The Board of Directors For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com) ABOUT GENOVIS Genovis is a global company that offers enzyme products that facilitate development and quality control of biologics to customers in the pharmaceutical and medical technology industries. The Company markets several enzyme products (“SmartEnzymes”) in innovative product formats all over the world. The organization consists of Genovis AB and the wholly owned subsidiary Genovis Inc. in the US. Genovis Inc. handles all sales of enzyme products on the North American market and Genovis AB handles sales in the rest of the world. Genovis shares are listed on Nasdaq First North Stockholm and Consensus is the Company’s Certified Adviser, t: +46(0) 31 745 50 00. This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.
Genovis publish a new share issue prospectus
| Source: Genovis AB
Attachments
